SCHEMBL9690992

SCHEMBL9690992

NC1=CC=C(C(=O)O)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
OAT P04181 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
BLM P54132 2/20 0.35
THRB P10828 1/20 0.35
PMP22 Q01453 1/20 0.35
KMT2A Q03164 1/20 0.35
GABRR1 P24046 2/20 0.34
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1355407 0.84 TSHR (0.42) TSHRMAPK1HSD17B10OATTDP1
SCHEMBL12166924 0.74 PTPN1 (0.43) TSHRHSD17B10BLMTHRBLMNA
SCHEMBL12189662 0.71 TSHR (0.34) TSHRMAPK1HSD17B10OATTDP1
SCHEMBL21264412 0.71 TSHR (0.34) TSHRMAPK1HSD17B10OATTDP1
SCHEMBL17993483 0.71 TSHR (0.34) TSHRMAPK1HSD17B10OATTDP1
SCHEMBL24755662 0.71 TSHR (0.34) TSHRMAPK1HSD17B10OATTDP1
SCHEMBL20663373 0.71 TSHR (0.33) TSHRMAPK1HSD17B10OATTDP1
SCHEMBL14754410 0.70 TSHR (0.36) TSHRMAPK1HSD17B10OATTDP1
SCHEMBL21985657 0.70 TSHR (0.43) TSHRMAPK1HSD17B10OATTDP1
SCHEMBL13802026 0.68 TSHR (0.32) TSHRMAPK1HSD17B10OATTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4199119-A1 ULTRA-THIN PLASMONIC SOLAR CELLS, METHODS FOR THEIR MANUFACTURE AND USE Peafowl Plasmonics AB (SE) 2023-06-21 EP disclosed
EP-3602645-B1 ULTRA-THIN PLASMONIC SOLAR CELLS, METHODS FOR THEIR MANUFACTURE AND USE PEAFOWL PLASMONICS AB (SE) 2023-06-07 EP disclosed
US-11242346-B2 Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) 2022-02-08 US disclosed
WO-2021226327-A1 NUCLEOTIDE CLEAVABLE LINKERS WITH RIGID SPACERS AND USES THEREOF Singular Genomics Systems, Inc. (US) 2021-11-11 WO disclosed
US-20200181147-A1 MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) 2020-06-11 US disclosed
EP-3309162-A1 TARGETED CONJUGATES OF PYRROLOBENZODIAZEPINES Seattle Genetics, Inc. (US) 2018-04-18 EP disclosed
US-5155248-A Reaction product of dibutyltin oxide with selected aromatic aminocarboxylic acid RHEIN CHEMIE RHEINAU GMBH (DE) 1992-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11242346-B2 Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof MTOR, RPTOR, RICTOR TSHR 2388/4885MAPK1 70/4885HSD17B10 1480/4885
US-20200181147-A1 MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF MTOR, RPTOR, RICTOR TSHR 2388/4885MAPK1 70/4885HSD17B10 1480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.